China’s Blue Sail Medical Co., Ltd (SHE: 002382) has received marketing approval from the National Medical Products Administration (NMPA) for its new coronary artery balloon dilation catheter, classified as a Category III medical device. This development marks a significant step forward in the treatment of complex coronary artery lesions, including chronic total occlusion (CTO).
The catheter, with a diameter specification of 0.7mm, is designed with a high-pressure resistant material capable of withstanding a rated burst pressure of 22 atm. This feature is crucial for the effective expansion of high resistance lesions. Additionally, the product boasts a state-of-the-art conveying system and hydrophilic coating, which enhance its pushing performance and overall operational excellence. These innovations are expected to facilitate easier clinical treatment of complex lesions.- Flcube.com
